Expanding Adult-Use And Medical Cannabis Markets Will Redefine The Industry

Key Takeaways

• Expansion into newly legalized states and premium product offerings position the company for sustained revenue growth and improved profitability as markets broaden.
  
• Vertical integration, strategic M&A, and digital-first initiatives enhance cost efficiency, operating margins, and reduce risk through focus on high-growth, regulated markets.
  
• Market oversupply, illicit competition, and regulatory uncertainty threaten revenues and margins, while acquisition-led expansion poses integration and execution risks to overall profitability.

Catalysts

About TerrAscend

TerrAscend Corp. cultivates, produces, and sells cannabis products in Canada and the United States.

What are the underlying business or industry changes driving this perspective?

• TerrAscend's ongoing expansion into newly adult-use and recently legalized states like Ohio, Maryland, and potentially Pennsylvania positions the company to benefit from broadening consumer and medical markets, which should drive sustained revenue growth as legalization progresses and market sizes increase.
  
• The company's ability to offer premium branded products across high-margin categories (such as vapes, edibles, and medical formulations) enables targeting of higher-value demographics as consumer perceptions of cannabis evolve, supporting improving gross margins and overall profitability.
  
• Increasing vertical integration and strategic M&A in core states (notably New Jersey and Ohio), alongside recently expanded cultivation and production capacity, improve scale and cost efficiencies, which is expected to enhance operating margins and accelerate cash flow.
  
• Accelerating adoption of a digital-first and direct-to-consumer approach (aided by operational upgrades and ERP system implementation) is likely to further lower customer acquisition costs and support stronger top-line growth and margins in the future.
  
• Exit from low-margin Michigan operations and redeployment of capital into higher-growth, regulated Northeastern markets (combined with improved regulatory enforcement against the illicit market) reduces risk exposure and supports the company's ability to grow EBITDA and strengthen net income margins.

TerrAscend Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming TerrAscend's revenue will grow by 1.4% annually over the next 3 years.
• Analysts are not forecasting that TerrAscend will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate TerrAscend's profit margin will increase from -25.8% to the average CA Pharmaceuticals industry of 1.2% in 3 years.
• If TerrAscend's profit margin were to converge on the industry average, you could expect earnings to reach $3.8 million (and earnings per share of $0.01) by about September 2028, up from $-77.3 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 184.6x on those 2028 earnings, up from -3.2x today. This future PE is greater than the current PE for the CA Pharmaceuticals industry at 37.5x.
• Analysts expect the number of shares outstanding to grow by 4.77% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.3%, as per the Simply Wall St company report.

TerrAscend Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

• TerrAscend's exit from Michigan due to extreme price collapse driven by the illicit market, oversupply, and unregulated synthetic hemp highlights the risk of similar adverse supply/demand and illicit competition dynamics emerging in other core markets, which could exert downward pressure on revenues and gross margins.
  
• Persistent price compression in New Jersey, with wholesale revenue declining 10.8% year-over-year and retail pricing having declined sharply from $8,000 to ~$4,700 per pound since adult-use legalization, signals ongoing risk of further margin compression across key markets if increased competition or new licenses are approved, ultimately impacting gross profit and EBITDA margins.
  
• The upcoming expansion of retail licenses in Maryland (with the state expected to add ~1,000 new licenses in coming years as part of a social equity program) increases the risk of local oversupply and market fragmentation, potentially reducing TerrAscend's retail same-store sales growth and placing pressure on both revenues and net margins.
  
• Ongoing reliance on acquisitions to fuel geographic expansion introduces execution risk; failure to successfully integrate new assets or overpaying for distressed properties could increase SG&A, dilute operational efficiencies, or result in unexpected write-downs, adversely affecting earnings stability and return on equity.
  
• High regulatory uncertainty at both the federal and state level, as well as unresolved challenges around illicit market enforcement and potential for rapid regulatory changes (e.g., federal legalization, interstate commerce), may result in abrupt shifts in competitive dynamics or compliance costs, potentially impacting revenues, net margins, and long-term profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of CA$1.876 for TerrAscend based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CA$2.25, and the most bearish reporting a price target of just CA$1.5.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $312.2 million, earnings will come to $3.8 million, and it would be trading on a PE ratio of 184.6x, assuming you use a discount rate of 6.3%.
• Given the current share price of CA$1.1, the analyst price target of CA$1.88 is 41.4% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.